NICE recommends Astellas' enzalutamide for prostate cancer

11 December 2015

The UK National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending enzalutamide to treat metastatic castration-resistant prostate cancer (mCRPC)

The drug, which is marketed as Xtandi by Japanese drug major Astellas Pharma (TYO: 4503), was recognized by the Appraisal Committee as being a valuable treatment for prostate cancer which has spread in people whose first treatment has failed, who have no or mild symptoms, and for whom chemotherapy is not yet clinically indicated.

The drug was found to delay chemotherapy and improve survival. It was also recognized as cost-effective.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK